PDF herunterladen
Klin Monbl Augenheilkd 2010; 227(9): 681-693
DOI: 10.1055/s-0029-1245606
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Intravitreale Medikamenteneingabe bei retinalem Venenverschluss – pathophysiologische Mechanismen und angewandte Substanzen

Intravitreal Drug Therapy for Retinal Vein Occlusion – Pathophysiological Mechanisms and Routinely Used DrugsN. Feltgen1 , A. Pielen2 , L. Hansen2 , B. Bertram3 , H. Agostini2 , G. B. Jaissle4 , H. Hoerauf1 , A. Stahl2, 5
  • 1Universitäts-Augenklinik Göttingen
  • 2Universitäts-Augenklinik Freiburg
  • 3Augenarztpraxis Aachen
  • 4Universitäts-Augenklinik Tübingen
  • 5Department of Ophthalmology, Children’s Hospital Boston, Harvard Medical School
Weitere Informationen

Publikationsverlauf

Eingegangen: 1.6.2010

Angenommen: 2.7.2010

Publikationsdatum:
15. September 2010 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Die intravitreale Medikamenteninjektion ist innerhalb weniger Jahre ein fester Bestandteil in der Behandlung des retinalen Venenverschlusses geworden. Bei den verwendeten Substanzen, von denen mittlerweile mehrere in großen randomisierten Studien getestet wurden, handelt es sich um Kortikosteroide einerseits und Inhibitoren des vaskulären endothelialen Gefäßwachstumsfaktors VEGF andererseits. Die Behandlungserfolge, die sich mit den meisten dieser Medikamente erzielen lassen, haben auch zu neuen Erkenntnissen der pathophysiologischen Vorgänge geführt. In dem vorliegenden Übersichtsartikel werden die aktuellen Substanzen und ihre Wirkungsweise diskutiert, die Daten der klinischen Studien kritisch evaluiert und die neue Therapieoption der intravitrealen Medikamenteneingabe in das bisher etablierte Behandlungsschema des retinalen Venenverschlusses eingefügt.

Abstract

The novel therapeutic principle of intravitreal drug therapy for retinal vein occlusion has become an integrated constituent of clinical practice over the last years. The two substance classes that have been evaluated in large randomised clinical trials so far are corticosteroids and inhibitors of vascular endothelial growth factor (VEGF). The reported treatment success of these intravitreally administered substances has lead not only to a paradigm shift in clinical care but has also advanced our understanding of the underlying pathophysiological principles of retinal vein occlusions. In this review the different substances are discussed, their mechanisms of action are analysed and the results of the large clinical trials available to date are critically evaluated. Furthermore, an approach to integrate these novel treatment options into the exisitng treatment regimes for retinal vein occlusions is suggested.

Schlüsselwörter

Retina - Pathologie - Glaskörper - intravitreale Injektion

Key words

retina - pathology - vitreous - intravitreal injection

Literatur

  • 1 Sedney S. Photocoagulation and retinal vein occlusion.  Documenta ophthalmologica. 1976;  40 1-241
    Google Scholar
  • 2 [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration] Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration.  Klin Monbl Augenheilkd. 2007;  224 559-566
    Google Scholar
  • 3 Lardenoye C W, Probst K, DeLint P J et al. Photoreceptor function in eyes with macular edema.  Investigative ophthalmology & visual science. 2000;  41 4048-4053
    Google Scholar
  • 4 Wu L, Martinez-Castellanos M A, Quiroz-Mercado H et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 2008;  246 81-87
    Google Scholar
  • 5 Stahl A, Feltgen N, Fuchs A et al. Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections.  Documenta ophthalmologica. 2009;  118 81-88
    Google Scholar
  • 6 Spaide R F, Chang L K, Klancnik J M et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.  American journal of ophthalmology. 2009;  147 298-306
    Google Scholar
  • 7 Gregori N Z, Gaitan J, Rosenfeld P J et al. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion.  Retina. 2008;  28 1325-1337
    Google Scholar
  • 8 Prager F, Michels S, Kriechbaum K et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial.  The British journal of ophthalmology. 2009;  93 452-456
    Google Scholar
  • 9 Jaissle G, Szurman P, Feltgen N et al. Predictive Factors for Functional Improvement after Intravitreal Bevacizumab Therapy for Macular Edema due to Branch Retinal Vein Occlusion. Joint Congress of the Asia Pacific Academy of Ophthalmology and the American Academy of Ophthalmology. Bali, Indonesia; 2010
    Google Scholar
  • 10 Wu L, Arevalo J F, Berrocal M H et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.  Retina. 2009;  29 1396-1403
    Google Scholar
  • 11 Stahl A, Struebin I, Hansen L L et al. Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment.  European journal of ophthalmology. 2010;  20 180-185
    Google Scholar
  • 12 Cugati S, Cikamatana L, Wang J J et al. Five-year incidence and progression of vascular retinopathy in persons without diabetes: the Blue Mountains Eye Study.  Eye. 2006;  20 1239-1245
    Google Scholar
  • 13 Cugati S, Wang J J, Knudtson M D et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts.  Ophthalmology. 2007;  114 520-524
    Google Scholar
  • 14 Cugati S, Wang J J, Rochtchina E et al. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study.  Archives of ophthalmology. 2006;  124 726-732
    Google Scholar
  • 15 Brown G. Central retinal vein obstruction: diagnosis and management. In RD R, ed Ophthalmology Annual.. East Norwalk: Appleton&Lange; 1985: 65-97
    Google Scholar
  • 16 David R, Zangwill L, Badarna M et al. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure.  Ophthalmologica Journal international d’ophtalmologie International journal of ophthalmology. 1988;  197 69-74
    Google Scholar
  • 17 Hayreh S S. Retinal vein occlusion. [Review] [64 refs].  Indian Journal of Ophthalmology. 1994;  42 109-132
    Google Scholar
  • 18 Seitz R. Die Netzhautgefäße. Ferdinand Enke Verlag. Stuttgart; 1962 1 ed: 175
    Google Scholar
  • 19 Nagaoka T, Yoshida A. Noninvasive evaluation of wall shear stress on retinal microcirculation in humans.  Investigative ophthalmology & visual science. 2006;  47 1113-1119
    Google Scholar
  • 20 Wiek J, Schade M, Wiederholt M et al. Haemorheological changes in patients with retinal vein occlusion after isovolaemic haemodilution.  The British journal of ophthalmology. 1990;  74 665-669
    Google Scholar
  • 21 Boyd S R, Zachary I, Chakravarthy U et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.  Archives of ophthalmology. 2002;  120 1644-1650
    Google Scholar
  • 22 Stahl A, Buchwald A, Martin G et al. Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema.  Retina. 2010;  ; im Druck
    Google Scholar
  • 23 Garci-Arumi J, Fonollosa A, Macia C et al. Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema.  Eye. 2009;  23 1066-1071
    Google Scholar
  • 24 Inomata Y, Hirata A, Takahashi E et al. Elevated erythropoietin in vitreous with ischemic retinal diseases.  Neuroreport. 2004;  15 877-879
    Google Scholar
  • 25 Semenza G L. Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis.  Hematol Oncol Clin North Am. 1994;  8 863-884
    Google Scholar
  • 26 Forsythe J A, Jiang B H, Iyer N V et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.  Mol Cell Biol. 1996;  16 4604-4613
    Google Scholar
  • 27 Chen J, Connor K M, Aderman C M et al. Erythropoietin deficiency decreases vascular stability in mice.  J Clin Invest. 2008;  118 526-533
    Google Scholar
  • 28 Chen J, Connor K M, Aderman C M et al. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy.  Investigative ophthalmology & visual science. 2009;  50 1329-1335
    Google Scholar
  • 29 Junk A K, Mammis A, Savitz S I et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury.  Proc Natl Acad Sci U S A. 2002;  99 10659-10664
    Google Scholar
  • 30 Kooij M A, Groenendaal van der F, Kavelaars A et al. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia.  Brain Res Rev. 2008;  59 22-33
    Google Scholar
  • 31 Watanabe D, Suzuma K, Matsui S et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.  The New England journal of medicine. 2005;  353 782-792
    Google Scholar
  • 32 Grasso G, Sfacteria A, Meli F et al. Neuroprotection by erythropoietin administration after experimental traumatic brain injury.  Brain Res. 2007;  1182 99-105
    Google Scholar
  • 33 Gunnarson E, Song Y, Kowalewski J M et al. Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection.  Proc Natl Acad Sci U S A. 2009;  106 1602-1607
    Google Scholar
  • 34 Friedman E A, L’Esperance F A, Brown C D et al. Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease.  Kidney Int Suppl. 2003(87);  S57-S63
    Google Scholar
  • 35 Chen J, Smith L E. A double-edged sword: erythropoietin eyed in retinopathy of prematurity.  J AAPOS. 2008;  12 221-222
    Google Scholar
  • 36 Lagreze W A, Feltgen N, Bach M et al. Feasibility of intravitreal erythropoietin injections in humans.  The British journal of ophthalmology. 2009;  93(12) 1667-1671
    Google Scholar
  • 37 Li W, Sinclair S H, Xu G T. Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema.  Ophthalmic Surg Lasers Imaging. 2010;  41 18-25
    Google Scholar
  • 38 Brown D M, Campochiaro P A, Singh R P et al. Ranibizumab for Macular Edema following Central Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study.  Ophthalmology. 2010;  ; online
    Google Scholar
  • 39 Quinlan P M, Elman M J, Bhatt A K et al. The natural course of central retinal vein occlusion.  American journal of ophthalmology. 1990;  110 118-123
    Google Scholar
  • 40 CVOS-Group . Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.  . [comment][erratum appears in Arch Ophthalmol 1997;115 (10): 1275]. Comment in: Arch Ophthalmol 1998; 116 (2): 260 – 261; PMID: 9 488 292 Archives of ophthalmology. 1997;  115 486-491
    Google Scholar
  • 41 Wroblewski J J, Wells 3rd  J A, Adamis A P et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.  Archives of ophthalmology. 2009;  127 374-380
    Google Scholar
  • 42 Haller J A, Bandello F, Belfort Jr R et al. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion.  Ophthalmology. 2010;  ; online
    Google Scholar
  • 43 Ip M S, Scott I U, VanVeldhuisen P C et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.  Archives of ophthalmology. 2009;  127 1101-1114
    Google Scholar
  • 44 McIntosh R L, Mohamed Q, Saw S M et al. Interventions for branch retinal vein occlusion: an evidence-based systematic review.  Ophthalmology. 2007;  114 835-854
    Google Scholar
  • 45 Hayreh S S, Hayreh M S. Hemi-central retinal vein occulsion. Pathogenesis, clinical features, and natural history.  Archives of ophthalmology. 1980;  98 1600-1609
    Google Scholar
  • 46 Scott I U, Ip M S, Van Veldhuisen P C et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6.  Archives of ophthalmology. 2009;  127 1115-1128
    Google Scholar
  • 47 Campochiaro P A, Heier J S, Feiner L et al. Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study.  Ophthalmology. 2010;  ; online
    Google Scholar
  • 48 Rogers S L, McIntosh R L, Lim L et al. Natural History of Branch Retinal Vein Occlusion: An Evidence-Based Systematic Review.  Ophthalmology. 2010;  117(6) 1094-1101 e5
    Google Scholar
  • 49 Priglinger S G, Wolf A H, Kreutzer T C et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.  Retina. 2007;  27 1004-1012
    Google Scholar
  • 50 McIntosh R L, Rogers S L, Lim L et al. Natural History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review.  Ophthalmology. 2010;  ; online
    Google Scholar
  • 51 Hansen L L. Central retinal vein occlusion. In Joussen A, Gardner T, Kirchhof B, eds Retinal Vascular Disease:. Springer; 2007
    Google Scholar
  • 52 Dithmar S, Hansen L L, Holz F G. [Retinal vein occlusions].  Ophthalmologe. 2003;  100 561-577 ; quiz 578
    Google Scholar
  • 53 Hayreh S S, Zimmerman M B, Beri M et al. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion.  Ophthalmology. 2004;  111 133-141
    Google Scholar
  • 54 BVOS. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group.  Archives of ophthalmology. 1986;  104 34-41
    Google Scholar
  • 55 CVOS-Group . A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.[comment].  Comment in: Ophthalmology 1996;103 (3): 352, discussion 353 – 354; PMID: 8 600 408, Comment in: Ophthalmology 1996; 103 (3): 352, discussion 353 – 354; PMID: 8 600 407, Comment in: Ophthalmology 1996; 103 (3): 352 – 354; PMID: 8 600 406. Ophthalmology. 1995;  102 1434-1444
    Google Scholar
  • 56 Brückner R. Central retinal vein occlusion and its therapy.  Ophthalmologica Journal international d’ophtalmologie International journal of ophthalmology. 1955;  129 325-326
    Google Scholar
  • 57 Blankenship G W. Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications.  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 1991;  229 62-65
    Google Scholar
  • 58 Penfold P L, Gyory J F, Hunyor A B et al. Exudative macular degeneration and intravitreal triamcinolone. A pilot study.  Australian and New Zealand journal of ophthalmology. 1995;  23 293-298
    Google Scholar
  • 59 Greenberg P B, Martidis A, Rogers A H et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion.  The British journal of ophthalmology. 2002;  86 247-248
    Google Scholar
  • 60 Jonas J B, Kreissig I, Degenring R F. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion.  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 2002;  240 782-783
    Google Scholar
  • 61 McAllister I L, Vijayasekaran S, Chen S D et al. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion.  American journal of ophthalmology. 2009;  147 838-846, 846 e831-e832
    Google Scholar
  • 62 Jonas J B, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases.  Progress in retinal and eye research. 2005;  24 587-611
    Google Scholar
  • 63 Zhang X, Bao S, Lai D et al. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas.  Diabetes. 2008;  57 1026-1033
    Google Scholar
  • 64 Edelman J L, Lutz D, Castro M R. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown.  Exp Eye Res. 2005;  80 249-258
    Google Scholar
  • 65 Wang K, Wang Y, Gao L et al. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression.  Biol Pharm Bull. 2008;  31 1541-1546
    Google Scholar
  • 66 Kunikata H, Shimura M, Nakazawa T et al. Chemokines in aqueous humour before and after intravitreal triamcinolone acetonide in eyes with macular oedema associated with branch retinal vein occlusion.  Acta Ophthalmol. 2010;  ; online
    Google Scholar
  • 67 Wilson C A, Berkowitz B A, Sato Y et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation.  Archives of ophthalmology. 1992;  110 1155-1159
    Google Scholar
  • 68 Jeanneteau F, Garabedian M J, Chao M V. Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect.  Proc Natl Acad Sci U S A. 2008;  105 4862-4867
    Google Scholar
  • 69 Kube T, Sutter M, Trittler R et al. Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone.  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 2006;  244 1385-1390
    Google Scholar
  • 70 Bobbili R B, Mathai A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema.  American journal of ophthalmology. 2006;  142 531 ; author reply 531 – 532
    Google Scholar
  • 71 Cekic O, Bardak Y, Tig S U et al. Hemodynamic response to intravitreal triamcinolone in eyes with macular edema : Intravitreal triamcinolone and ocular blood flow.  Int Ophthalmol. 2007;  27(5) 313-319
    Google Scholar
  • 72 Chen S D, Sundaram V, Lochhead J et al. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion.  American journal of ophthalmology. 2006;  141 876-883
    Google Scholar
  • 73 Degenring R F, Kamppeter B, Kreissig I et al. Morphological and functional changes after intravitreal triamcinolone acetonide for retinal vein occlusion.  Acta ophthalmologica Scandinavica. 2003;  81 548-550
    Google Scholar
  • 74 Flynn H W, Scott I U. Intravitreal triamcinolone acetonide for macular edema associated with diabetic retinopathy and venous occlusive disease: it’s time for clinical trials.  Archives of ophthalmology. 2005;  123 258-259
    Google Scholar
  • 75 Goff M J, Jumper J M, Yang S S et al. Intravitreal Triamcinolone Acetonide Treatment of Macular Edema Associated with Central Retinal Vein Occlusion.  Retina. 2006;  26 896-901
    Google Scholar
  • 76 Gregori N Z, Rosenfeld P J, Puliafito C A et al. One-Year Safety and Efficacy of Intravitreal Triamcinolone Acetonide for the Management of Macular Edema Secondary to Central Retinal Vein Occlusion.  Retina. 2006;  26 889-895
    Google Scholar
  • 77 Hirano Jr Y, Sakurai E, Yoshida M et al. Comparative Study on Efficacy of a Combination Therapy of Triamcinolone Acetonide Administration with and without Vitrectomy for Macular Edema Associated with Branch Retinal Vein Occlusion.  Ophthalmic research. 2007;  39 207-212
    Google Scholar
  • 78 Ip M S, Gottlieb J L, Kahana A et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.  Archives of ophthalmology. 2004;  122 1131-1136
    Google Scholar
  • 79 Jonas J B, Akkoyun I, Kamppeter B et al. Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion.  European journal of ophthalmology. 2005;  15 751-758
    Google Scholar
  • 80 Jonas J B, Akkoyun I, Kamppeter B et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide.  Eye. 2005;  19 65-71
    Google Scholar
  • 81 Krepler K, Ergun E, Sacu S et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study.  Acta ophthalmologica Scandinavica. 2005;  83 600-604
    Google Scholar
  • 82 Moschos M M, Brouzas D, Loukianou E et al. Intraocular triamcinolone acetonide for macular edema due to CRVO. A multifocal-ERG and OCT study.  Documenta ophthalmologica. 2007;  114 1-7
    Google Scholar
  • 83 Oh J Y, Seo J H, Ahn J K et al. Early versus Late Intravitreal Triamcinolone Acetonide for Macular Edema associated with Branch Retinal Vein Occlusion.  Korean J Ophthalmol. 2007;  21 18-20
    Google Scholar
  • 84 Patel P J, Zaheer I, Karia N. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion.  Eye (Lond). 2008;  22(1) 60-64
    Google Scholar
  • 85 Ramezani A, Entezari M, Moradian S et al. Intravitreal triamcinolone for acute central retinal vein occlusion, a randomized clinical trial.  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 2006;  244 1601-1606
    Google Scholar
  • 86 Hayashi K, Hayashi H. Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion.  American journal of ophthalmology. 2005;  139 972-982
    Google Scholar
  • 87 Byun Y J, Roh M I, Lee S C et al. Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion.  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 2010;  248(7) 963-971
    Google Scholar
  • 88 Guthoff R, Meigen T, Hennemann K et al. Comparison of Bevacizumab and Triamcinolone for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion – A Matched-Pairs Analysis.  Ophthalmologica Journal international d’ophtalmologie International journal of ophthalmology. 2009;  224 126-132
    Google Scholar
  • 89 Cheng K C, Wu W C, Chen K J. Intravitreal triamcinolone acetonide vs. bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.  Eye. 2009;  23 2023-2033
    Google Scholar
  • 90 Wu W C, Cheng K C, Wu H J. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion.  Eye. 2009;  23 2215-2222
    Google Scholar
  • 91 Nehme A, Edelman J. Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes.  Investigative ophthalmology & visual science. 2008;  49 2030-2038
    Google Scholar
  • 92 Gan I M, Ugahary L C, Dissel J T et al. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis.  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 2005;  243 1186-1189
    Google Scholar
  • 93 Zhang Z G, Zhang van L, Jiang Q et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain.  J Clin Invest. 2000;  106 829-838
    Google Scholar
  • 94 Kaur C, Foulds W S, Ling E A. Hypoxia-ischemia and retinal ganglion cell damage.  Clin Ophthalmol. 2008;  2 879-889
    Google Scholar
  • 95 Noma H, Funatsu H, Mimura T et al. Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion.  European journal of ophthalmology. 2008;  18 1017-1019
    Google Scholar
  • 96 Noma H, Funatsu H, Yamasaki M et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6.  American journal of ophthalmology. 2005;  140 256-261
    Google Scholar
  • 97 Noma H, Minamoto A, Funatsu H et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion.  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 2006;  244 309-315
    Google Scholar
  • 98 Kim K S, Chang H R, Song S. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion.  Acta Ophthalmol. 2008;  86 925-927
    Google Scholar
  • 99 Shimura M, Yasuda K. Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease.  The British journal of ophthalmology. 2010;  94 381-383
    Google Scholar
  • 100 Shetty R, Pai S A, Vincent A et al. Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema.  Documenta ophthalmologica. 2008;  116 129-135
    Google Scholar
  • 101 Bonini-Filho M, Costa R, Calucci D et al. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.  American journal of ophthalmology. 2009;  147 1022-1030
    Google Scholar
  • 102 Neubauer A, Kook D, Haritoglou C et al. Bevacizumab and retinal ischemia.  Ophthalmology. 2007;  114 2096
    Google Scholar
  • 103 Wroblewski J J, Wells 3 rd J A, Gonzales C R. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion.  American journal of ophthalmology. 2010;  149 147-154
    Google Scholar
  • 104 Badala F. The treatment of branch retinal vein occlusion with bevacizumab.  Current opinion in ophthalmology. 2008;  19 234-238
    Google Scholar
  • 105 Gregori N Z, Rattan G H, Rosenfeld P J et al. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion.  Retina. 2009;  29 913-925
    Google Scholar
  • 106 Gutierrez J C, Barquet L A, Caminal J M et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion.  Clin Ophthalmol. 2008;  2 787-791
    Google Scholar
  • 107 Iturralde D, Spaide R F, Meyerle C B et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.  Retina. 2006;  26 279-284
    Google Scholar
  • 108 Jaissle G B, Leitritz M, Gelisken F et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion.  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 2009;  247 27-33
    Google Scholar
  • 109 Jaissle G B, Ziemssen F, Petermeier K et al. [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion]. Bevacizumab zur Therapie des sekundären Makulaödems nach venösen Gefäßverschlüssen.  Ophthalmologe. 2006;  103 471-475
    Google Scholar
  • 110 Kriechbaum K, Michels S, Prager F et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.  The British journal of ophthalmology. 2008;  92 518-522
    Google Scholar
  • 111 Rabena M D, Pieramici D J, Castellarin A A et al. Intravitreal Bevacizumab (Avastin) in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.  Retina. 2007;  27 419-425
    Google Scholar
  • 112 Schaal K B, Hoh A E, Scheuerle A et al. [Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion] Bevacizumab zur Therapie des Makulaödems infolge venöser retinaler Gefäßverschlüsse.  Ophthalmologe. 2007;  104 285-289
    Google Scholar
  • 113 Kreutzer T C, Alge C S, Wolf A H et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.  The British journal of ophthalmology. 2008;  92 351-355
    Google Scholar
  • 114 Stahl A, Agostini H, Hansen L L et al. Bevacizumab in retinal vein occlusion-results of a prospective case series.  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 2007;  245 1429-1436
    Google Scholar
  • 115 Tao Y, Hou J, Jiang Y R et al. Intravitreal bevacizumab vs. triamcinolone acetonide for macular oedema due to central retinal vein occlusion.  Eye (Lond). 2010;  24(5) 810-815
    Google Scholar
  • 116 Wu L, Arevalo J F, Roca J A et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.  Retina. 2008;  28 212-219
    Google Scholar
  • 117 Abegg M, Tappeiner C, Wolf-Schnurrbusch U et al. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab.  BMC Ophthalmol. 2008;  8 18
    Google Scholar
  • 118 Ach T, Hoeh A E, Schaal K B et al. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion.  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 2009;  248(2) 155-159
    Google Scholar
  • 119 Ahmadi A A, Chuo J Y, Banashkevich A et al. The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion.  Canadian journal of ophthalmology. 2009;  44 154-159
    Google Scholar
  • 120 Ahmadieh H, Moradian S, Malihi M. Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab.  Int Ophthalmol. 2005;  26 191-193
    Google Scholar
  • 121 Algvere P V, Wendt von G, Gudmundsson J et al. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin).  Acta Ophthalmol. 2009;  ; online
    Google Scholar
  • 122 Chalam K V, Keshavamurthy R, Brar V S. Spectral domain OCT documented resolution of recalcitrant macular edema after intravitreal bevacizumab in branch retinal vein occlusion.  European journal of ophthalmology. 2008;  18 831-833
    Google Scholar
  • 123 Chung E J, Hong Y T, Lee S C et al. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion.  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 2008;  246 1241-1247
    Google Scholar
  • 124 Costa R A, Jorge R, Calucci D et al. Intravitreal Bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO Study.  Retina. 2007;  27 141-149
    Google Scholar
  • 125 Fish G E. Intravitreous bevacizumab in the treatment of macular edema from branch retinal vein occlusion and hemisphere retinal vein occlusion (an AOS thesis).  Transactions of the American Ophthalmological Society. 2008;  106 276-300
    Google Scholar
  • 126 Funk M, Kriechbaum K, Prager F et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.  Investigative ophthalmology & visual science. 2009;  50 1025-1032
    Google Scholar
  • 127 Hoeh A E, Ach T, Schaal K B et al. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.  Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie. 2009;  247 1635-1641
    Google Scholar
  • 128 Kondo M, Kondo N, Ito Y et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis.  Retina. 2009;  29 1242-1248
    Google Scholar
  • 129 Matsumoto Y, Freund K B, Peiretti E et al. Rebound macular edema following bevacizumab (avastin) therapy for retinal venous occlusive disease.  Retina. 2007;  27 426-431
    Google Scholar
  • 130 Pai S A, Shetty R, Vijayan P B et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.  American journal of ophthalmology. 2007;  143 601-606
    Google Scholar
  • 131 Pournaras J A, Nguyen C, Vaudaux J D et al. Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (avastin[r]): preliminary results.  Klin Monatsbl für Augenheilkd. 2008;  225 397-400
    Google Scholar
  • 132 Rensch F, Jonas J B, Spandau U H. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.  Acta Ophthalmol. 2009;  87(1) 77-81
    Google Scholar
  • 133 Rosenfeld P J, Fung A E, Puliafito C A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion.  Ophthalmic Surg Lasers Imaging. 2005;  36 336-339
    Google Scholar
  • 134 Russo V, Barone A, Conte E et al. Bevacizumab Compared with Macular Laser Grid Photocoagulation for Cystoid Macular Edema in Branch Retinal Vein Occlusion.  Retina. 2009;  29(4) 511-515
    Google Scholar
  • 135 Spandau U, Wickenhauser A, Rensch F et al. Intravitreal bevacizumab for branch retinal vein occlusion.  Acta ophthalmologica Scandinavica. 2007;  85 118-119
    Google Scholar
  • 136 Scott I U, Oden N L, Vanveldhuisen P C et al. Standard Care vs Corticosteroid in Retinal Vein Occlusion Study Report 7: Incidence of Intravitreal Silicone Oil Droplets Associated With Staked-on vs. Luer Cone Syringe Design.  American journal of ophthalmology. 2009;  148(5) 725-732 e7
    Google Scholar
  • 137 Chu Y K, Chung E J, Kwon O W et al. Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection.  Eye. 2008;  22 895-899
    Google Scholar
  • 138 Beck R W, Edwards A R, Aiello L P et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema.  Archives of ophthalmology. 2009;  127 245-251
    Google Scholar
  • 139 Bashshur Z F, Ma’luf R N, Allam S et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion.  Archives of ophthalmology. 2004;  122 1137-1140
    Google Scholar
  • 140 Ladas I D, Karagiannis D A, Rouvas A A et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections.  Retina. 2009;  29 313-318
    Google Scholar
  • 141 Bakri S J, Ekdawi N S. Intravitreal silicone oil droplets after intravitreal drug injections.  Retina. 2008;  28 996-1001
    Google Scholar
  • 142 Georgopoulos M, Polak K, Prager F et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin).  The British journal of ophthalmology. 2009;  93 457-462
    Google Scholar
  • 143 Kocabora M S, Ozbilen K T, Serefoglu K. Intravitreal silicone oil droplets following pegaptanib injection.  Acta Ophthalmol. 2010;  88 e44-e45
    Google Scholar
  • 144 Ness T, Feltgen N, Agostini H et al. Toxic vitreitis outbreak after intravitreal injection.  Retina. 2010;  30 332-338
    Google Scholar
  • 145 Sato T, Emi K, Ikeda T et al. Severe intraocular inflammation after intravitreal injection of bevacizumab.  Ophthalmology. 2010;  117(3) 512-516, 516 e1–2
    Google Scholar
  • 146 Yamashiro K, Tsujikawa A, Miyamoto K et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch.  Retina. 2010;  30 485-490
    Google Scholar
  • 147 Yenerel N M, Dinc U A, Gorgun E. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection.  J Ocul Pharmacol Ther. 2008;  24 362-363
    Google Scholar
  • 148 Regillo C D, Brown D M, Abraham P et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.  American journal of ophthalmology. 2008;  145 239-248
    Google Scholar
  • 149 Brown D M, Michels M, Kaiser P K et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.  Ophthalmology. 2009;  116 57-65 e55
    Google Scholar
  • 150 Brown D M, Kaiser P K, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.  The New England journal of medicine. 2006;  355 1432-1444
    Google Scholar
  • 151 Rosenfeld P J, Brown D M, Heier J S et al. Ranibizumab for neovascular age-related macular degeneration.  The New England journal of medicine. 2006;  355 1419-1431
    Google Scholar
  • 152 Chung Y R, Lee K, Cho E H et al. Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology.  Eye. 2010;  ; online
    Google Scholar
  • 153 Sakamoto A, Tsujikawa A, Ota M et al. Evaluation of potential visual acuity in eyes with macular oedema secondary to retinal vein occlusion.  Clin Experiment Ophthalmol. 2009;  37 208-216
    Google Scholar
  • 154 Bates D O, Cui T G, Doughty J M et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.  Cancer Res. 2002;  62 4123-4131
    Google Scholar
  • 155 Woolard J, Wang W Y, Bevan H S et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.  Cancer Res. 2004;  64 7822-7835
    Google Scholar
  • 156 Perrin R M, Konopatskaya O, Qiu Y et al. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.  Diabetologia. 2005;  48 2422-2427
    Google Scholar
  • 157 Magnussen A L, Rennel E S, Hua J et al. VEGF-A165b is cytoprotective and anti-angiogenic in the retina.  Investigative ophthalmology & visual science. 2010;  ; online
    Google Scholar

PD Dr. Nicolas Feltgen

Augenklinik, Universitäts-Klinikum

Robert-Koch-Straße 40

37075 Göttingen

Telefon: ++ 49/05 51/39 61 43

Fax: ++ 49/5 51/39 67 87

eMail: nicolas.feltgen@med.uni-goettingen.de

      >